ACCESSWIRE

3425 articles with ACCESSWIRE

• With Medtech Growth in Full Swing, Newswire's Financial Distribution Provides Key Market Entry

  9/21/2020

  ​​​Americans have grown accustomed to the changes brought about by the coronavirus pandemic, including the ways in which the crisis has impacted healthcare processes.

• BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit

  9/21/2020

  BioVie Inc., a clinical-stage company developing innovative drug therapies for liver disease, announced that Jonathan Adams, the Company's President & COO, will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on Monday, September 21, 2020 at 1:40 p.m. ET.

• Arizona State University/Halberd Corp. Covid-19 Research Program Progress - Successful Covid Spike Protein Disease Antigen Re-Creation!

  9/21/2020

  Halberd Corporation released a progress update on the research being conducted in conjunction with Arizona State University researchers.

• Pardeep Nijhawan Acquires Beneficial Ownership of Additional Securities of Edesa Biotech, Inc.

  9/18/2020

  Dr. Pardeep Nijhawan announces that his beneficial ownership of common shares in the capital of Edesa Biotech, Inc. has increased by more than 2% of the issued and outstanding Common Shares from the amount reported in the early warning report Dr. Nijhawan filed dated May 11, 2020.

• BioVie Inc. Announces Nasdaq Listing and Pricing of $15.7 Million Public Offering

  9/17/2020

  BioVie Inc., a clinical-stage company developing innovative drug therapies for liver disease, announced the pricing of an underwritten public offering of 1,565,200 shares of Class A common stock at a public offering price of $10.00 per share for aggregate gross proceeds of $15,652,000 prior to deducting underwriting discounts, commissions, and other offering expenses.

• Arizona State University/Halberd Corp. Outline Partnership 2nd Stage Goals of $1.4 M Covid-19 Program

  9/17/2020

  Halberd Corporation outlined the specifics of the second stage goals of the $1.4 Million seven-phase research project with Arizona State University.

• MorphoSys and Incyte to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas

  9/17/2020

  Analyst and investor conference call and webcast scheduled for Tuesday, September 29, 2020 at 9:00 a.m. EDT / 3:00 p.m. CEST

• Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

  9/17/2020

  Dyadic International, Inc. today announced collaboration with Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui") (SSE:600276) to apply Dyadic's C1 technology to the development of selected Hengrui biologic drug(s).

• Applied UV, Inc. Subsidiary, SteriLumen, Inc. Installs First Ultraviolet Light Disinfecting Devices at Mt. Sinai St. Luke's Hospital as Part of Evaluation Study

  9/17/2020

  Applied UV, Inc. announced that its subsidiary, SteriLumen, Inc., has installed its Disinfecting System in the first of 17 patient bathrooms at Mount Sinai's Morningside Hospital adjoining Columbia University in New York, NY in connection with a study to be conducted by Mt.

• AIM ImmunoTech Highlights Start of Recruitment in Roswell Park Clinical Trial Incorporating Ampligen in the Treatment of Cancer Patients with Mild or Moderate COVID-19

  9/16/2020

  AIM ImmunoTech Inc. announced that recruitment has begun in Roswell Park Comprehensive Cancer Center's Phase 1/2a clinical study of the effectiveness of rintatolimod in combination with interferon alpha-2b in treating cancer patients with mild or moderate COVID-19 infection, which is caused by the SARS-CoV-2 virus.

• Solos Endoscopy's MammoView(R) Now for use with Low Temperature Sterilization System

  9/16/2020

  Solos Endoscopy, Inc. is pleased to announce it has completed the compatibility testing of its MammoView product line with The STERIS V-PRO 1 Low Temperature Sterilization System.

• Jaguar Health Establishes World-Class Scientific Strategy Team to Support Newly Launched Mental Health Entheogen Therapeutics Initiative

  9/16/2020

  Jaguar Health announced today the formation of a scientific strategy team (SST) to support the company's recently launched mental health,

• NHI Provides Business Update - Sep 16, 2020

  9/16/2020

  National Health Investors, Inc. provided a business update regarding its monthly contractual rent collections, deferral update, and average occupancy from its three largest senior housing operators.

• NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19

  9/16/2020

  NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials.

• Cantabio Pharmaceuticals receives grant from Michael J. Fox Foundation to develop a novel DJ-1 protein-based biomarker for Parkinson's Disease

  9/16/2020

  Grant enables the development of new detection technologies for DJ-1 in biofluids to create a new biomarker for the potential early diagnosis and tracking of the progression of Parkinsons disease

• Pascal Biosciences to Present at International Cannabinoid Derived Pharmaceutical Summit

  9/16/2020

  Pascal Biosciences Inc. (TSXV:PAS) oday Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements in each of Pascal's three cannabinoid programs. The title of his presentation is "Identifying and Validating Mechanism of Action In Vivo and In Vitro".

• Havn Life Sciences Announces Listing Approval on the Frankfurt Stock Exchange

  9/16/2020

  Havn Life Sciences Inc. is pleased to announce that it has been accepted to list its common shares on the Frankfurt Stock Exchange under the trading symbol.

• Enzolytics, Inc. Announces Execution of Letter of Intent with BioClonetics Immunotherapeutics, Inc. (With Additional Update on 2020 Initiatives)

  9/16/2020

  Enzolytics, Inc. today announced the execution of a non-binding letter of intent (the "LOI") to merge with BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics") a biotech company located in Dallas Texas.

• Aytu BioScience to Report Fourth Quarter FY 2020 Results and Business Update on Thursday, September 24, 2020

  9/16/2020

  Live Conference Call and Webcast at 4:30 ET

• Sunshine Biopharma Secures $2,000,000 + Financing for Coronavirus Treatment

  9/15/2020

  Sunshine Biopharma Inc. today announced that it has received the first tranche of $250,000 as part of a committed minimum financing of $2 Million with RB Capital Partners Inc.